The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
December 2nd 2024
Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.
November 27th 2024
November 26th 2024
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Patients with PsA More Likely to Experience Side Effects of Methotrexate
"This risk-to-benefit profile has a different connotation for patients because, although a therapy may improve certain aspects of their disease, it may also have a substantial impact on their quality of life.”
Paul M Peloso, MD, MSc: Izokibep Significantly Improves Symptoms of Psoriatic Arthritis
Rheumatology Network interviewed Paul M. Peloso, MD, MSc, Chief Medical Officer at Acelyrin, to discuss recent phase 2 data examining the safety and efficacy of izokibep in the treatment of psoriatic arthritis.
Pulmonary Involvement More Likely in Treatment-Naïve Pediatric Patients
Although pulmonary complications in pediatric patients may cause functional impairment and increase mortality, studies detecting lung involvement in children with treatment-naïve, newly diagnosed patients with rheumatic disease are scarce.
FDA Approves Citrate-Free, High-Concentration Adalimumab Biosimilar Adalimumab-bwwd
The US Food and Drug Administration approved of the citrate-free, high-concntration (100 mg/mL) formulation of adalimumab-bwwd, a biosimilar of adalimumab, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.
Psoriatic Arthritis Remission Strongly Associated with Alleviation of Psoriasis Symptoms
“Given the complex nature of PsA, patients should also be involved in defining their treatment goals, as every patient may have different perspectives on the target for therapy and the means to achieve it.”
Rheumatoid Arthritis Quiz: Vaccinating Patients Taking Immunosuppressive Medications
August 12th 2022Immunosuppressive medication can interfere with the immune response to vaccines, so treatment may need to be held or the timing or type of vaccinations amended. Test your knowledge of vaccinating rheumatoid arthritis patients taking immunosuppressive therapies in this quiz.
COVID-19 Vaccine Minimally Impacts Risk of Gout Flares
"COVID-19 vaccines are effective against severity of SARS-COV-2 infection, but there has been a concern regarding their effect on the risk of flares in patients with gout, which are associated with health-related quality of life, healthcare resource utilization, and work productivity."
Vitamin D Supplementation Linked to Pain Reduction in Fibromyalgia
Despite previous evidence showing the benefits of vitamin D supplementation in patients with fibromyalgia and chronic widespread musculoskeletal pain, controversy still exists over the role of 25OHD in the treatment of these diseases.
Updated Vaccination Guidance for Patients with Rheumatic and Musculoskeletal Diseases
The American College of Rheumatology announced updated vaccination guidance for patients with rheumatic diseases, including expanding indications for certain vaccines for those receiving immunosuppressive medications, medication management, and vaccination delay.
New Guideline on Vaccination Recommendations for Patients with Rheumatic and Musculoskeletal Disease
August 3rd 2022The new treatment guideline addressed the possibility of differing safety and effectiveness outcomes among patients with rheumatic and musculoskeletal disease regarding vaccination compared with the general population.